Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, aesthetic medical products specialist Syneron Medical (Nasdaq: ELOS) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Syneron's business and see what CAPS investors are saying about the stock right now.

Syneron facts

Headquarters (Founded) Yokneam Illit, Israel (2000)
Market Cap $373.8 million
Industry Healthcare equipment
Trailing-12-Month Revenue $220.8 million
Management CEO Louis Scafuri (since 2009)
CFO Asaf Alperovitz (since 2010)
Return on Equity (Average, Past 3 Years) (15%)
Cash/Debt $151.0 million / $0
Competitors Cutera
Cynosure
Lumenis

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 774 members who have rated Syneron believe the stock will outperform the S&P 500 going forward.

Just last month, one of those bulls, Motley Fool co-founder David Gardner (TMFSpiffyPop), took another shot at Syneron:

This former Rule Breaker has bounced back pretty well from our sell recommendation in 2009. It has a lot of cash (always did), so the underlying business isn't priced for much. I'll rejoin the fray on this one and give it another green thumb. Please note, this may be a contrary indicator: I struck out in my first at-bat with [Syneron].

What do you think about Syneron, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.